Forte Biosciences, Inc. - Common Stock (FBRX)
CUSIP: 34962G208
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 12,506,886
- Total 13F shares
- 9,809,779
- Share change
- +4,775,290
- Total reported value
- $127,063,335
- Price per share
- $12.93
- Number of holders
- 33
- Value change
- +$62,289,077
- Number of buys
- 23
- Number of sells
- 8
Quarterly Holders Quick Answers
What is CUSIP 34962G208?
CUSIP 34962G208 identifies FBRX - Forte Biosciences, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 34962G208:
Top shareholders of FBRX - Forte Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD |
13D/G
13F
|
Company |
10%
|
1,268,086
|
$13,378,307 | +$6,618,184 | 30 Jun 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
7.4%
|
920,000
|
$7,387,600 | — | 31 Mar 2025 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
7.3%
|
910,609
|
$7,066,326 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13D/G
13F
|
Company |
5%
|
617,667
|
$6,516,387 | +$89,063 | 30 Jun 2025 | |
| BVF INC/IL |
13F
|
Company |
4.8%
|
594,282
|
$4,611,628 | — | 31 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
13D/G
|
Company |
8%
from 13D/G
|
593,088
|
$4,602,363 | — | 31 Mar 2025 | |
| Cable Car Capital, LP |
13F
|
Company |
1.8%
|
219,604
|
$1,704,127 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.6%
|
204,822
|
$1,589,419 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13D/G
|
— |
2.5%
|
163,935
|
$1,209,840 | $0 | 31 Dec 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
13D/G
|
Company |
0.8%
from 13D/G
|
89,191
|
$692,122 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.71%
|
88,951
|
$690,260 | — | 31 Mar 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.56%
|
70,429
|
$546,529 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.48%
|
60,082
|
$466,270 | — | 31 Mar 2025 | |
| Hubert C. Chen |
3/4/5
|
President and Chief Scientific Officer |
—
mixed-class rows
|
183,405
mixed-class rows
|
$150,704 | — | 01 Jan 2024 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.15%
|
18,469
|
$143,319 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.12%
|
14,605
|
$113,335 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.05%
|
6,803
|
$52,791 | — | 31 Mar 2025 | |
| AlphaQuest LLC |
13F
|
Company |
0.03%
|
4,217
|
$32,724 | — | 31 Mar 2025 | |
| Garde Capital, Inc. |
13F
|
Company |
0.03%
|
3,960
|
$30,730 | — | 31 Mar 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.03%
|
3,328
|
$26,000 | — | 31 Mar 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
1,792
|
$13,906 | — | 31 Mar 2025 | |
| Farallon Capital Partners, L.P. |
13D/G
|
Dapice Joshua J. |
3.4%
|
221,027
|
$12,130 | $0 | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
527
|
$4,090 | — | 31 Mar 2025 | |
| COMERICA BANK |
13F
|
Company |
0%
|
155
|
$1,203 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
151
|
$1,172 | — | 31 Mar 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
104
|
$807 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
46
|
$357 | — | 31 Mar 2025 | |
| PRIVATE TRUST CO NA |
13F
|
Company |
0%
|
42
|
$326 | — | 31 Mar 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
12
|
$93 | — | 31 Mar 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
8
|
$62 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
3
|
$23 | — | 31 Mar 2025 | |
| REAP Financial Group, LLC |
13F
|
Company |
0%
|
3
|
$23 | — | 31 Mar 2025 | |
| Donald Allen Williams |
3/4/5
|
Director |
—
class O/S missing
|
50,000
|
— | — | 20 Aug 2024 | |
| Lawrence Eichenfield |
3/4/5
|
Director |
—
class O/S missing
|
50,000
|
— | — | 20 Aug 2024 | |
| Barbara K. Finck |
3/4/5
|
Director |
—
class O/S missing
|
31,000
|
— | — | 19 Mar 2025 | |
| David W. Gryska |
3/4/5
|
Director |
—
class O/S missing
|
31,000
|
— | — | 20 Mar 2025 | |
| Richard G. Vincent |
3/4/5
|
Director |
—
class O/S missing
|
31,000
|
— | — | 20 Mar 2025 | |
| Scott C. Brun |
3/4/5
|
Director |
—
class O/S missing
|
31,000
|
— | — | 20 Mar 2025 | |
| Shivpreet Singh Kapoor |
3/4/5
|
Director |
—
class O/S missing
|
31,000
|
— | — | 20 Mar 2025 | |
| Stephen K. Doberstein |
3/4/5
|
Director |
—
class O/S missing
|
31,000
|
— | — | 20 Mar 2025 | |
| Steven Kornfeld |
3/4/5
|
Director |
—
class O/S missing
|
31,000
|
— | — | 20 Mar 2025 | |
| Patricia S. Walker |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 01 Jun 2022 |
Institutional Holders of Forte Biosciences, Inc. - Common Stock (FBRX) as of Q2 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.